| Basics |
Veru Inc.
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers.
|
| IPO Date: |
February 25, 1999 |
| Sector: |
Consumer Staples |
| Industry: |
Personal Products |
| Market Cap: |
$49.37M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.18 | 3.87%
|
| Avg Daily Range (30 D): |
$0.09 | 4.10%
|
| Avg Daily Range (90 D): |
$0.05 | 3.66%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.15M |
| Avg Daily Volume (30 D): |
.68M |
| Avg Daily Volume (90 D): |
1.42M |
| Trade Size |
| Avg Trade Size (Sh.): |
199 |
| Avg Trade Size (Sh.) (30 D): |
369 |
| Avg Trade Size (Sh.) (90 D): |
392 |
| Institutional Trades |
| Total Inst.Trades: |
665 |
| Avg Inst. Trade: |
$1.41M |
| Avg Inst. Trade (30 D): |
$2.88M |
| Avg Inst. Trade (90 D): |
$2.3M |
| Avg Inst. Trade Volume: |
.2M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.71M |
| Avg Closing Trade (30 D): |
$6.81M |
| Avg Closing Trade (90 D): |
$3.7M |
| Avg Closing Volume: |
296.04K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$.3
|
$-.5
|
$-.05
|
|
Diluted EPS
|
|
|
|
|
Revenue
|
$ 8.81M
|
$ .48M
|
$ .97M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -32.26M
|
$ -7.33M
|
$ -7.9M
|
|
Operating Income / Loss
|
$ -36.01M
|
$ -7.55M
|
$ -8.12M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -14.14M
|
$ -5.01M
|
$ -6.59M
|
|
PE Ratio
|
|
|
|
|
|
|
